22
Participants
Start Date
December 28, 2021
Primary Completion Date
September 19, 2022
Study Completion Date
September 19, 2022
APD418
Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
APD418
Participants will receive a single dose of APD418 as an IV infusion.
Placebo
Participants will receive a single dose of APD418 matching placebo as an IV infusion.
University Clinical Centre of Serbia, Belgrade
Institute for Cardiovascular Diseases Dedinje, Belgrade
Clinical Hospital Center Bezanijska Kosa, Belgrade
Konstantinopouleio General Hospital of Nea Ionia - Patision ''Agia Olga'', Nea Ionia
Immanuel Hospital Bernau Brandenburg Heart Center, Bernau bei Berlin
Universitatsmedizin Greifwald, Greifswald
Institute for Cardiovascular Diseases of Vojvodina, Kamenitz
Healthcare Center Uzice, Užice
James A. Haley Veterans' Hospital, Tampa
Clinical Center of Kragujevac, Kragujevac
General University Hospital of Larissa, Larissa
University of Wisconsin, Madison
Interbalkan European Medical Center, Pylaia
Kerckhoff-Klinik Forschungsgesellschaft GmbH, Bad Nauheim
UnityPoint Health - Methodist Hospital, Peoria
UTHealth, Houston
Health Science Center Utah, Salt Lake City
American Heart of Poland S.A., Gniezno
Krakowski Szpital Specjalistyczny im. Jana Pawla II, Krakow
Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego, Wroclaw
Clinical Hospital Centre Zemun, Belgrade
Lead Sponsor
Arena is a wholly owned subsidiary of Pfizer
INDUSTRY
Pfizer
INDUSTRY